Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPALA: Intrapleural PDT and Nivolumab in Malignant Pleural Mesothelioma
NCT04400539Phase 2Recruiting
- Sponsor
- CHU de Lille
- Start
- May 2022
- Primary completion
- May 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, 5-aminolevulinic acid in malignant pleural mesothelioma (MPM), sponsored by CHU de Lille. Started May 2022; status: recruiting.
02
Drugs
nivolumab5-aminolevulinic acid
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04400539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04400539.